2. Signaling Pathways
  3. Epigenetics
  4. Histone Methyltransferase
  5. Histone Methyltransferase Isoform
  6. Histone Methyltransferase Inhibitor

Histone Methyltransferase Inhibitor

Histone Methyltransferase Inhibitors (197):

Cat. No. Product Name Effect Purity
  • HY-114340
    LEM-14
    		Inhibitor 98.06%
    LEM-14 is a potent NSD2 inhibitor with an IC50 of 132 µM. LEM-14 has the potential for the research of multiple myeloma.
  • HY-155170
    MTDH-SND1 blocker 1
    		Inhibitor 99.33%
    MTDH-SND1 blocker 1 (compound C26-A6) is an inhibitor of the MTDH-SND1 protein. MTDH-SND1 blocker 1 inhibits cancer metastasis.
  • HY-151576
    PRMT5:MEP50 PPI
    		Inhibitor 98.70%
    PRMT5:MEP50 PPI is a novel PRMT5:MEP50 protein-protein interaction (PRMT5:MEP50 PPI) inhibitor, shows anti-tumor activity and anti-proliferative activity of lung and prostate cancer cells.
  • HY-148458
    EZH2-IN-14
    		Inhibitor 99.02%
    EZH2-IN-14 is a selective EZH2 (Histone Methyltransferase) inhibitor with an IC50 of 12 nM. EZH2-IN-14 inhibits the methyltransferase activity of EZH2/PRC2 (that is, reducing H3K27me3). EZH2-IN-14 shows >200-fold selective for EZH2 over the highly homologous H3K27 methyltransferase EZH1.
  • HY-147230
    EZH2-IN-13
    		Inhibitor 99.72%
    EZH2-IN-13 is a potent EZH2 inhibitor, for details please refer to compound 73 in patent WO2017139404. EZH2-IN-13 can be used to study cancers or precancerous lesions associated with EZH2 activity.
  • HY-153191
    EZH2-IN-15
    		Inhibitor 99.68%
    EZH2-IN-15 is a EZH2 inhibitor. EZH2-IN-15 has anti-tumor activity, and can be used for research of H3K27me3-dependent tumors.
  • HY-124101
    PDAT
    		Inhibitor ≥98.0%
    PDAT is a noncompetitive indolethylamine-N-methyltransferase (INMT) inhibitor with a Ki of 84 μM for rabbit lung INMT (rabINMT).
  • HY-155815
    MS9715
    		Inhibitor
    MS9715 is a potent and seletive NSD3-targeting PROTAC. MS9715 is designed by BI-9321, which binds NSD3’s PWWP1 domain, with an E3 ligase VHL ligand. MS9715 has the potental for NSD3-dependent cancer treatment research.
  • HY-141716
    SW2_110A
    		Inhibitor 99.19%
    SW2_110A is a selective chromobox 8 chromodomain (CBX8 ChD) inhibitor with a Kd of 800 nM. SW2_110A shows minimal 5-fold selectivity for CBX8 ChD over all other CBX paralogs in vitro.
  • HY-161024
    AC1Q3QWB
    		Inhibitor 99.39%
    AC1Q3QWB upregulates CDKN1A and SOX17 by interrupting the HOTAIR-EZH2 interaction and enhances the efficacy of Tazemetostat in endometrial cancer.
  • HY-162308
    NSD-IN-3
    		Inhibitor ≥98.0%
    NSD-IN-3 (compound 3) is a potent nuclear receptor binding SET domain (NSD) inhibitor. NSD-IN-3 inhibits NSD2-SET and NSD3-SET with IC50 values of 0.81 μM and 0.84 μM, respectively. NSD-IN-3 inhibits histone H3K36 dimethylation and decreases the expression of NSDs-targeted genes in non-small cell lung cancer cells. NSD-IN-3 induces s-phase cell cycle arrest and apoptosis.
  • HY-132233A
    DDO-2093 dihydrochloride
    		Inhibitor 98.52%
    DDO-2093 dihydrochloride is a potent MLL1-WDR5 protein-protein interaction inhibitor (IC50=8.6 nM; Kd=11.6 nM) with antitumor activity. DDO-2093 dihydrochloride selectively inhibits the catalytic activity of MLL complex.
  • HY-132970
    EED ligand 1
    		Inhibitor 99.93%
    EED ligand 1 is a diverse, potent, and efficacious inhibitor that target the EED subunit of the polycomb repressive complex 2 (PRC2) methyltransferase.
  • HY-120444
    MS0124
    		Inhibitor 99.79%
    MS0124 is a potent selective G9a-like protein (GLP) inhibitor with IC50 values of 13±4 nM and 440±63 nM for GLP and G9a,respectively.
  • HY-147185
    PRMT7-IN-1
    		Inhibitor 98.70%
    PRMT7-IN-1 (Compound 14) is a PRMT7 inhibitor with an IC50 of 2.1 μM. PRMT7-IN-1 shows anticancer activity against different cancer cells.
  • HY-161759
    MS152
    		Inhibitor 99.36%
    MS152 is an oral bioactive inhibitor of EHMT2/G9a. MS152 reactivats maternally silenced Prader-Willi syndrome (PWS) genes in brain and liver tissues of PWS mouse models.
  • HY-15214
    CARM1-IN-3
    		Inhibitor 98.90%
    CARM1-IN-3 (compound 17b) is a potent and selective co-activator associated arginine methyltransferase (CARM1) inhibitor with IC50 values of 0.07, >25 µM for CARM1 and CARM3, respectively.
  • HY-160801
    HKYK-0030
    		Inhibitor 99.38%
    HKYK-0030 is an inhibitor for MTDH-SND1 protein-protein interaction. HKYK-0030 exhibits inhibitory activity against cancer metastasis.
  • HY-161575
    NSD2 ligand 1
    		Inhibitor 99.76%
    NSD2 ligand 1 is a NSD2 ligand. NSD2 ligand 1 can be used for synthesis of LLC0424 (HY-161574) (a PROTAC NSD2 degrader).
  • HY-12991A
    BIX-01338 hydrate
    		Inhibitor 98.81%
    BIX-01338 hydrate is a histone lysine methyltransferase inhibitor.